Inogen expands product portfolio, global reach and innovation pipeline through strategic collaboration with Yuwell – ulaganje.com

Goleta, Calif.-(Business Wire)–Inogen, Inc. (NASDAQ: INGN), a medical technology company that provides innovative respiratory products for use in the home environment, today announced that it has entered into a strategic collaboration with Jiangsu Yuyue Medical (TASE 🙂 Equipment and Supply Co., Ltd. (002223.SZ, Yuwell), a global home healthcare device manufacturer with a comprehensive portfolio of respiratory products.

The strategic collaboration is expected to expand inogen’s (NASDAQ: product portfolio) distribution of certain respiratory products in the United States and select other territories, expand and enhance inogen’s innovation pipeline through R&D collaboration, and accelerate Inogen’s brand entry into the Chinese market. In addition, Yuwell, through its subsidiary, has agreed to invest approximately $27.2 million in Inogen, representing a 9.9% joint equity stake, further cementing the partnership and strengthening Inogen’s balance sheet.

The collaboration with Yuwell is a central step in accelerating Inogen’s growth trajectory. By expanding our product portfolio, global presence and enhancing our innovation pipeline, we expect to be well positioned to capture new market opportunities, said Kevin Smith, President and CEO. This collaboration supports our commitment to deliver long-term value to our shareholders and reinforces our vision of establishing Inogen as a platform for best-in-class respiratory solutions for patients worldwide. We are confident that our collaboration with Yuwell will play a crucial role in our continued success. “

Alex Wu, chairman of Yuwell, added, Inogen is a leader in the respiratory therapy market, and our strategic collaboration gives both parties the opportunity to expand their geographic reach and further meet the needs of patients around the world. Yuwell shares Inogen’s commitment to developing and providing innovative, quality products, and we believe that together we can significantly impact the lives of respiratory patients. Together, Yuwell and Inogen aim to define the next generation of respiratory products.

The collaboration agreement will be effective immediately, while the equity purchase from Inogen is expected to close during the first quarter of 2025, subject to certain customary closing conditions.

About Inogen

Inogen, Inc. (NASDAQ: INGN) is a leading global medical technology company offering innovative respiratory products for use in the home environment. Inogen supports respiratory patient care by developing, manufacturing and marketing innovative, best-in-class respiratory therapy devices used to provide care to patients suffering from chronic respiratory conditions. Inogen partners with patients, physicians, home medical equipment providers and distributors to make its respiratory therapy products widely available, allowing patients the opportunity to manage the impact of their disease.

For more information, visit www.inogen.com.

Inogen has used and intends to continue to use the investor relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and complying with disclosure obligations under Regulation FD.

About Yuwell

Since its founding in 1998, Yuwell has been at the forefront of providing superior medical device solutions to enhance patient care and improve home healthcare worldwide. Yuwell (0022233.SZ) has a revenue of US$1 billion in 2023 and has a broad product portfolio across respiratory treatment, diabetes management, electronic diagnostic products, first aid and rehabilitation solutions, among other areas.

With an unwavering commitment to clinical excellence, Yuwell delivers high-quality, medically reliable products that empower healthcare professionals to achieve superior patient outcomes.

With 9 state-of-the-art R&D and 7 advanced manufacturing facilities, Yuwell’s global presence spans more than 100 countries and supports more than 300,000 healthcare facilities. Yuwell touches the lives of patients worldwide by bringing professional, user-friendly medical devices into the home.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial prospects, growth strategies and expected operating results are forward-looking statements. Words such as AIMS, believe, anticipate, plan, expect, will, intend, potential, possible and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks and uncertainties related to the potential benefits of working with Yuwell; satisfaction of the closing conditions under the securities purchase agreement relating to the equity investment; time of closing capital investment; market acceptance of its products; Competition; its sales, marketing and distribution capabilities; its planned sales, marketing and research and development activities; and risks associated with international operations. For a detailed discussion of these and other risks that could affect Inogen’s business and financial performance, see the risk factors section of its Annual Report on Form 10-K for the period ended December 31, 2023, its Quarterly Report on Form 10- Q for the calendar quarter ended March 31, 2024 and in other filings with the Securities and Exchange Commission. These future statements speak only as of the date of this Agreement. Inogen disclaims any obligation to update these forward-looking statements, except as may be required by law.

See the original version on BusinessWire.com: https://www.businesswire.com/news/home/20250126900450/en/

ir@inogen.net

Source: Inogen, Inc.